The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
To evaluate the efficacy and safety of envafolimab combined with concurrent chemoradiotherapy in limited stage small cell lung cancer.
Lung Neoplasms
DRUG: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)|DRUG: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
2-year PFS rate, 2-yaer progression-free survival rate, From date of randomization until the date of first documented progression or date of death from any cause up to 24 months.
ORR, Objective Response Rate, From date of randomization until the date of first documented progression or date of death from any cause up to 24 months.|DCR, Disease control rate, From date of randomization until the date of intolerance the toxicity or PD up to 24 months.|DOR, Duration of response, From date of randomization until the date of intolerance the toxicity or PD up to 24 months.|OS, Overall survival, From date of randomization until the date of death(up to 24 months)|Adverse event rate Adverse event rate Adverse event rate, Number of participants with adverse events as a measure of safety and tolerability, From date of randomization until the date of toxicity or PD (up to 24 months)
Envafolimab is the world's first subcutaneous injection of PD-L1 monoclonal antibody. Suitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene defects (dMMR).